×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NYSE:EBS

Emergent BioSolutions (EBS) Stock Forecast, Price & News

$35.22
+3.03 (+9.41%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$31.60
$35.26
50-Day Range
$27.97
$44.20
52-Week Range
$27.61
$68.03
Volume
1.08 million shs
Average Volume
689,291 shs
Market Capitalization
$1.77 billion
P/E Ratio
12.10
Dividend Yield
N/A
Beta
0.98
30 days | 90 days | 365 days | Advanced Chart
Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

Emergent BioSolutions logo

About Emergent BioSolutions

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
CUSIP
29089Q10
Employees
2,416
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.79 billion
Cash Flow
$9.37 per share
Book Value
$31.35 per share

Profitability

Net Income
$230.90 million
Pretax Margin
12.83%

Debt

Price-To-Earnings

Miscellaneous

Free Float
45,019,000
Market Cap
$1.77 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/28/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.72 out of 5 stars

Medical Sector

51st out of 1,424 stocks

Pharmaceutical Preparations Industry

18th out of 681 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -













Emergent BioSolutions (NYSE:EBS) Frequently Asked Questions

Is Emergent BioSolutions a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Emergent BioSolutions stock.
View analyst ratings for Emergent BioSolutions
or view top-rated stocks.

When is Emergent BioSolutions' next earnings date?

Emergent BioSolutions is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Emergent BioSolutions
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) announced its earnings results on Thursday, April, 28th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by $0.06. The biopharmaceutical company earned $307.50 million during the quarter, compared to analysts' expectations of $282.54 million. Emergent BioSolutions had a trailing twelve-month return on equity of 16.05% and a net margin of 8.96%. Emergent BioSolutions's revenue was down 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.53 earnings per share.
View Emergent BioSolutions' earnings history
.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its FY 2022 earnings guidance on Thursday, March, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.40 billion, compared to the consensus revenue estimate of $1.44 billion.

What price target have analysts set for EBS?

4 brokers have issued 12-month price targets for Emergent BioSolutions' shares. Their forecasts range from $30.00 to $77.00. On average, they expect Emergent BioSolutions' stock price to reach $49.17 in the next year. This suggests a possible upside of 39.6% from the stock's current price.
View analysts' price targets for Emergent BioSolutions
or view top-rated stocks among Wall Street analysts.

Who are Emergent BioSolutions' key executives?
Emergent BioSolutions' management team includes the following people:
  • Mr. Robert G. Kramer Sr., CEO, Pres & Exec. Director (Age 65, Pay $1.93M)
  • Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 58, Pay $858.61k) (LinkedIn Profile)
  • Mr. Adam R. Havey, Exec. VP & COO (Age 51, Pay $843.1k)
  • Mr. Atul Saran, Exec. VP & Chief Strategy and Devel. Officer (Age 49, Pay $820.66k)
  • Mr. Robert G. Burrows, VP of Investor Relations
  • Ms. Jennifer L. Fox, Exec. VP of External Affairs, Gen. Counsel & Corp. Sec.
  • Ms. Coleen Glessner, Exec. VP of Global Quality and Ethics & Compliance
  • Ms. Lynn Kieffer, VP of Corp. Communications
  • Ms. Katherine Strei, Exec. VP of HR & Chief HR Officer (Age 60)
What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions CEO Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among Emergent BioSolutions' employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Square (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.38%), Vanguard Group Inc. (10.26%), State Street Corp (6.91%), Earnest Partners LLC (4.12%), Dimensional Fund Advisors LP (2.72%) and Invesco Ltd. (1.77%). Company insiders that own Emergent BioSolutions stock include Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends for Emergent BioSolutions
.

Which major investors are selling Emergent BioSolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Snyder Capital Management L P, Vanguard Group Inc., Earnest Partners LLC, Invesco Ltd., Assenagon Asset Management S.A., Prudential Financial Inc., and UBS Group AG.
View insider buying and selling activity for Emergent BioSolutions
or view top insider-selling stocks.

Which major investors are buying Emergent BioSolutions stock?

EBS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Federated Hermes Inc., Global Alpha Capital Management Ltd., JPMorgan Chase & Co., and Russell Investments Group Ltd..
View insider buying and selling activity for Emergent BioSolutions
or or view top insider-buying stocks.

How do I buy shares of Emergent BioSolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $35.22.

How much money does Emergent BioSolutions make?

Emergent BioSolutions has a market capitalization of $1.77 billion and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $2.91 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

Emergent BioSolutions employs 2,416 workers across the globe.

What is Emergent BioSolutions' official website?

The official website for Emergent BioSolutions is www.emergentbiosolutions.com.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at [email protected], or via fax at 301-795-1899.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.